Loading...
Loading...
Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults over 50 in developed countries. The macula -- the small, specialized region at the center of the retina responsible for sharp, detailed vision -- progressively deteriorates, robbing patients of their ability to read, recognize faces, drive, and perform other tasks that depend on central vision. Peripheral vision is typically preserved, which distinguishes AMD from conditions like glaucoma.
For paraoptometrics, AMD is a critical topic because you perform several of the key screening and monitoring tests: Amsler grid testing, visual acuity measurement, OCT imaging, and fundus photography. Understanding the disease well enough to educate patients about home monitoring, AREDS2 supplements, and when to seek urgent care makes you an essential part of the AMD management team.
The CPO and CPOA exams test your knowledge of AMD types, staging, risk factors, the role of testing, and patient education. This guide covers each of these areas with the clinical detail you need.
AMD is divided into two forms based on whether abnormal blood vessel growth is present. This distinction is clinically critical because it determines prognosis, urgency, and treatment approach.
Accounts for approximately 90% of all AMD cases. The hallmark finding is drusen -- yellowish deposits of waste material that accumulate between the retinal pigment epithelium (RPE) and Bruch's membrane. Small, hard drusen are extremely common with aging and not necessarily concerning. Large, soft drusen (over 125 microns, about the width of a retinal vein at the disc margin) are the clinical marker of AMD.
As dry AMD progresses, the RPE becomes irregular -- showing areas of hyperpigmentation (clumping) and hypopigmentation (atrophy). In the most advanced stage, called geographic atrophy, the RPE and overlying photoreceptors die in well-demarcated patches. Geographic atrophy causes permanent scotomas (blind spots) in the affected areas and slowly expands over years.
Vision loss in dry AMD is typically gradual. There is no cure, but AREDS2 supplements can slow progression in intermediate and advanced stages. Importantly, dry AMD can convert to wet AMD at any time.
Accounts for only about 10% of AMD cases but causes approximately 90% of severe vision loss from AMD. The defining feature is choroidal neovascularization (CNV) -- abnormal new blood vessels growing from the choroid through Bruch's membrane under or into the retina. These vessels are fragile and leaky, releasing fluid and blood into the retinal layers.
The hallmark symptom is sudden metamorphopsia -- straight lines appear wavy or bent. Patients may also notice a sudden decrease in central vision, a new central dark spot, or difficulty reading. On OCT, subretinal or intraretinal fluid is visible. On fundus examination, subretinal hemorrhage or exudates may be present.
Treatment with anti-VEGF injections (ranibizumab, aflibercept, bevacizumab, faricimab) can stabilize or improve vision in many patients by blocking the growth factor that drives abnormal vessel growth. Early detection and prompt treatment significantly improve outcomes, which is why daily Amsler grid monitoring is so important.
| Stage | Findings | Vision Impact | Management |
|---|---|---|---|
| Early AMD | Medium drusen (63-125 microns), no pigment changes | Usually none | Monitor, lifestyle counseling, no AREDS2 indicated |
| Intermediate AMD | Large drusen (>125 microns) and/or pigment changes | Mild to moderate; may notice difficulty in dim light | AREDS2 supplements recommended, regular monitoring |
| Late Dry AMD | Geographic atrophy (RPE and photoreceptor loss) | Significant central vision loss | AREDS2, low-vision rehabilitation, emerging therapies |
| Late Wet AMD | Choroidal neovascularization, fluid, hemorrhage | Rapid, potentially severe central vision loss | Urgent anti-VEGF injections, ongoing monitoring |
Age is the strongest overall risk factor. AMD prevalence increases sharply after age 50 and continues to rise with each decade. By age 75, the prevalence of intermediate or advanced AMD is substantial. This is why comprehensive eye exams are increasingly important with age.
The strongest modifiable risk factor. Smokers have 2-4 times the risk of AMD compared to non-smokers. Smoking increases oxidative damage to the retina and reduces macular pigment density. The risk remains elevated for years after quitting but does decrease over time. Document smoking status and encourage cessation.
Genetics play a significant role. First-degree relatives of AMD patients have a substantially higher risk. Several genetic variants have been identified, particularly in complement factor H (CFH) and ARMS2 genes. Family history should be documented during patient intake.
Caucasian race, obesity, cardiovascular disease, and UV exposure are additional risk factors. A diet low in leafy green vegetables (which provide lutein and zeaxanthin for macular pigment) may also contribute. AMD is less common in African Americans, though it does occur.
Paraoptometrics perform several tests critical for AMD detection and monitoring. Each provides different information, and together they give the doctor a comprehensive picture of disease status and progression.
Amsler Grid
A simple but powerful screening tool: a grid of horizontal and vertical lines with a central fixation dot. The patient covers one eye, fixates on the center, and reports any areas where lines appear wavy (metamorphopsia), broken, missing, or blurred. Any distortion is a red flag for macular pathology, particularly wet AMD conversion. The paraoptometric administers this test in-office and educates patients on daily home monitoring.
Visual Acuity Testing
Central VA is the primary functional measure in AMD. Decreased VA, especially near vision, may indicate macular involvement. A sudden drop in VA in a patient with known dry AMD should raise concern for wet AMD conversion. Document VA carefully at each visit for comparison.
OCT (Optical Coherence Tomography)
OCT is the single most important imaging tool for AMD management. It provides cross-sectional images of the retinal layers, allowing visualization of drusen, RPE changes, geographic atrophy, subretinal and intraretinal fluid, and pigment epithelial detachments. In patients receiving anti-VEGF treatment for wet AMD, OCT is performed at every visit to assess treatment response. The paraoptometric captures the scans and ensures image quality.
Fundus Photography
Color fundus photos document drusen, pigment changes, hemorrhage, and exudates. Widefield imaging captures a larger area of the retina. Serial photographs allow comparison of drusen size and distribution over time, detection of new hemorrhage, and documentation of geographic atrophy expansion. These images become part of the permanent medical record.
AMD patient education can directly impact visual outcomes. Patients who understand their condition, monitor at home, and seek prompt care when changes occur have better prognoses. The paraoptometric often spends more time with the patient than the doctor and is well-positioned to reinforce these messages.
Teach patients to check the Amsler grid every day, one eye at a time, while wearing their reading glasses. They should fixate on the central dot and note any areas of waviness, distortion, blurriness, or missing sections. Any new changes should prompt an urgent call to the office. Provide a physical grid and demonstrate proper technique before the patient leaves.
For patients with intermediate or advanced AMD, the doctor may recommend AREDS2 supplements. Help patients understand these are a specific formulation (vitamins C, E, zinc, copper, lutein, zeaxanthin) that has been shown to reduce progression risk by about 25% -- not a general multivitamin. Patients should look for products labeled "AREDS2 formula" and take them as directed. These supplements do not reverse existing damage but help protect remaining vision.
Patients must understand that any sudden change in vision -- new distortion, sudden blur, or new dark spot -- could indicate wet AMD conversion and requires urgent evaluation. This is not something that can wait for the next scheduled appointment. Early treatment of wet AMD with anti-VEGF injections can prevent significant vision loss, but delays reduce treatment effectiveness.
Smoking cessation is the single most impactful lifestyle change for AMD risk reduction. A diet rich in dark leafy greens (kale, spinach, collard greens) provides lutein and zeaxanthin, which form the protective macular pigment. Regular cardiovascular exercise, maintaining a healthy weight, and wearing UV-protective sunglasses are also beneficial.
Dry-to-Wet AMD Conversion: Recognize the Signs
A patient with known dry AMD who reports new metamorphopsia (wavy or distorted vision), a sudden decrease in visual acuity, or a new central dark spot may be converting to wet AMD. This requires urgent evaluation -- ideally same-day OCT to look for subretinal or intraretinal fluid. If wet AMD is confirmed, anti-VEGF treatment should begin as soon as possible. Delays of even weeks can result in permanent vision loss.
The retinal layers, macula, fovea, and photoreceptor organization relevant to AMD.
Camera setup, image quality, and documenting macular changes for AMD monitoring.
Another major retinal condition paraoptometrics screen for regularly.
Browse all CPO and CPOA study topics organized by category.
Dry (non-exudative) AMD accounts for about 90% of cases and is characterized by drusen (yellow deposits beneath the retina), RPE changes, and in advanced stages, geographic atrophy (areas where the RPE and photoreceptors have died). Vision loss is typically gradual. Wet (exudative) AMD involves abnormal blood vessel growth beneath the retina (choroidal neovascularization). These fragile vessels leak fluid and blood, causing rapid and often severe central vision loss. While wet AMD accounts for only 10% of cases, it causes about 90% of severe vision loss from AMD.
AREDS2 (Age-Related Eye Disease Study 2) supplements contain a specific formulation of vitamins C (500 mg), E (400 IU), zinc (80 mg), copper (2 mg), lutein (10 mg), and zeaxanthin (2 mg). They are recommended for patients with intermediate AMD (large drusen) or advanced AMD in one eye, as the study showed they reduce the risk of progression to advanced AMD by about 25%. They are NOT recommended for people with no AMD or only early AMD (small drusen). The paraoptometric should understand these recommendations for patient education.
The Amsler grid is a simple at-home monitoring tool that detects metamorphopsia (distortion of straight lines) and new scotomas (missing areas) in the central visual field. These changes can indicate the development of wet AMD or worsening of existing disease. AMD patients should check the Amsler grid in each eye separately every day. Any new distortion, waviness, or missing areas is a reason to contact the eye doctor urgently -- early detection and treatment of wet AMD significantly improves visual outcomes.
Yes. Dry AMD can convert to wet AMD at any time. This conversion occurs when abnormal new blood vessels grow from the choroid beneath the retina (choroidal neovascularization). The conversion can happen suddenly, which is why regular monitoring with Amsler grid and clinical exams is essential. Signs of conversion include new metamorphopsia (distortion), sudden decrease in central vision, or new fluid/hemorrhage visible on OCT or fundus examination. Prompt treatment with anti-VEGF injections can significantly reduce vision loss if wet AMD is caught early.
OCT (optical coherence tomography) is invaluable in AMD management. In dry AMD, OCT shows drusen as dome-shaped elevations of the RPE, RPE irregularities, and in advanced dry AMD, areas of geographic atrophy where the retinal layers are thinned and the RPE is absent. In wet AMD, OCT reveals subretinal or intraretinal fluid, pigment epithelial detachment (PED), and sometimes the neovascular membrane itself. OCT is used both for initial diagnosis and for monitoring treatment response in wet AMD patients receiving anti-VEGF injections.
Smoking is the strongest modifiable risk factor for AMD. Current smokers have a 2-4 times higher risk of developing AMD compared to non-smokers, and the risk remains elevated for years after quitting. Smoking is thought to increase oxidative stress in the retina and reduce macular pigment density. Smoking cessation counseling is one of the most impactful things a healthcare provider can do for AMD risk reduction. The paraoptometric should document smoking status and reinforce cessation when appropriate.